Evidence map›Paper›PMID 38087107›Full record

ArticleThe AAPS journal2023

Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing.

Ankur Sharma, Xin Liu, Vishal Chandra, Rajani Rai, Doris M Benbrook, Sukyung Woo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The AAPS journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ankur Sharma *Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, 1110 N. Stonewall Ave., Oklahoma City, Oklahoma, 73117-1200, USA.
Xin Liu *Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, 352 Pharmacy Building, Buffalo, New York, 14214, USA.
Vishal ChandraDepartment of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 975 NE 10th St, BRC 1217A, Oklahoma City, Oklahoma, 73104, USA.
Rajani RaiDepartment of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 975 NE 10th St, BRC 1217A, Oklahoma City, Oklahoma, 73104, USA.
Doris M BenbrookDepartment of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 975 NE 10th St, BRC 1217A, Oklahoma City, Oklahoma, 73104, USA.
Sukyung WooDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, 352 Pharmacy Building, Buffalo, New York, 14214, USA. skwoo@buffalo.edu.
University of Oklahoma Health Sciences Center · USUniversity at Buffalo, State University of New York · US

Funding

Ovarian Cancer ChemopreventionR01CA196200 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BENBROOK, DORIS MANGIARACINA · 2015 to 2019
$2.5M
Targeting HPV Consequences in a Cervical Cancer Clinical TrialR01CA200126 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BENBROOK, DORIS MANGIARACINA, MOORE, KATHLEEN N. · 2016 to 2021
$2.1M
Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibitionR01CA258546 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Sukyung Woo · 2022 to 2026
$2.0M
NCI NIH HHS R01 CA196200NCI NIH HHS R01 CA200126NCI NIH HHS R01 CA258546
6 · The paper itself

Abstract

SHetA2 is a promising, orally active small molecule with anticancer properties that target heat shock proteins. In this study, we aimed to investigate the pharmacodynamic (PD) effects of SHetA2 using preclinical in vitro and in vivo models of ovarian cancer and establish a physiologically based pharmacokinetic (PBPK)/PD model to describe their relationships with SHetA2 concentrations in mice. We found that daily oral administration of 60 mg/kg SHetA2 for 7 days resulted in consistent plasma PK and tissue distribution, achieving tumor drug concentrations required for growth inhibition in ovarian cancer cell lines. SHetA2 effectively induced cyclin D1 degradation in cancer cells in a dose-dependent manner, with up to 70% reduction observed and an IC

Indexed as

Cyclin D1Ovarian NeoplasmsAnimalsChromansFemaleHeterograftsHumansMiceThiones(((4-nitrophenyl)amino)(2,2,4,4-tetramethyl thiochroman-6-yl)amino) methane-1-thioneChromansCyclin D1Thionesanticancer drugcyclin D1ovarian cancerSHetA2

Identifiers

PMID38087107
PMCPMC11610768
OpenAlexW4389626671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.